8-K: Tempest Therapeutics Announces Positive Phase 3 Trial Progress and Third Quarter 2024 Financial Results

Tempest Therapeutics reported third quarter 2024 financial results, highlighted by FDA approval to proceed with a pivotal Phase 3 trial for amezalpat in combination therapy for liver cancer and a collaboration with Roche.

Summary

• Tempest Therapeutics announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company received a Study May Proceed letter from the FDA for a pivotal Phase 3 trial of amezalpat in combination therapy for first-line hepatocellular carcinoma (HCC).
• Tempest has partnered with Roche, who will supply atezolizumab for the Phase 3 trial, while Tempest will sponsor and lead the study.
• The company also received final funding approval from the National Cancer Institute (NCI) to advance TPST-1495 into a Phase 2 trial for Familial Adenomatous Polyposis (FAP).
• Tempest ended the quarter with $22.1 million in cash and cash equivalents, down from $39.2 million at the end of 2023.
• Subsequent to the quarter end, the company raised an additional $19.9 million through an at-the-market (ATM) offering.
• The net loss for the quarter was $10.6 million, or $0.41 per share, compared to a net loss of $6.8 million, or $0.48 per share, for the same period in 2023.
• Research and development expenses increased to $7.6 million for the quarter, up from $4.2 million in the same period of 2023.
• General and administrative expenses were $3.0 million for the quarter, compared to $2.4 million in the same period of 2023.
• The company's cash used in operating activities for the nine months ended September 30, 2024 was $22.9 million.
• The net loss for the nine months ended September 30, 2024 was $28.0 million, or $1.19 per share, compared to a net loss of $22.0 million, or $1.57 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and a key partnership, but the increased losses and cash burn are a concern. The sentiment is positive but tempered by financial realities.

Positives

• The FDA's Study May Proceed letter for the Phase 3 trial of amezalpat is a significant regulatory milestone.
• The collaboration with Roche provides crucial support for the Phase 3 trial.
• NCI funding for the TPST-1495 Phase 2 trial is a positive development for the company's pipeline.
• The expansion of the leadership team strengthens the company's clinical expertise.
• The potential to shorten the time to primary analysis by up to 8 months is a positive development for the Phase 3 trial.
• The company successfully raised additional capital after the quarter end.

Negatives

• The company's cash balance decreased from $39.2 million at the end of 2023 to $22.1 million at the end of the third quarter 2024.
• The net loss for the quarter increased to $10.6 million from $6.8 million in the same period of 2023.
• Research and development expenses increased significantly to $7.6 million for the quarter.
• General and administrative expenses also increased to $3.0 million for the quarter.

Risks

• The company's cash runway may be limited given the current burn rate.
• Unexpected safety or efficacy data during clinical trials could impact the development of the company's product candidates.
• Lower than expected clinical trial site activation or enrollment rates could delay the progress of the trials.
• Changes in the regulatory environment could impact the approval process for the company's product candidates.
• Unexpected litigation or other disputes could negatively impact the company's operations.

Future Outlook

The company plans to advance TPST-1495 into a Phase 2 study in patients with FAP in 2024 or early 2025 and expects to disclose data from the TPST-1495 Phase 1 combination arm in patients with advanced endometrial cancer in 2025. The company also anticipates the Phase 3 trial of amezalpat will be a success.

Management Comments

• Stephen Brady, president and chief executive officer of Tempest, stated that the team continued to move amezalpat successfully towards the pivotal study, achieving important milestones on both the regulatory and business fronts.
• Mr. Brady also mentioned that based on the positive randomized Phase 2 data and a Phase 3 plan they believe is designed for success, they were thrilled to receive broad agreement with the FDA.

Industry Context

This announcement is significant in the oncology space, particularly for liver cancer, as it highlights the progress of a novel therapy (amezalpat) into a pivotal Phase 3 trial. The collaboration with Roche, a major player in oncology, further validates the potential of Tempest's approach. The advancement of TPST-1495 also indicates a broader pipeline development strategy.

Comparison to Industry Standards

• The collaboration with Roche is similar to other partnerships in the biotech industry where larger pharmaceutical companies support the development of promising therapies from smaller companies.
• The Phase 3 trial design for amezalpat, including the standard-of-care control arm and pre-specified early efficacy analysis, aligns with industry best practices for late-stage clinical trials.
• The increase in R&D expenses is typical for a clinical-stage biotech company advancing multiple programs, and is comparable to companies such as Arcus Biosciences and Exelixis who are also developing novel cancer therapies.
• The cash burn rate and net losses are also typical for companies at this stage of development, and are comparable to other companies in the sector such as Iovance Biotherapeutics and Mirati Therapeutics.

Management Changes

Stakeholder Impact

• Shareholders may view the clinical trial progress and Roche partnership positively, but the increased losses and cash burn may be a concern.
• Employees may be encouraged by the company's progress and expansion of the leadership team.
• Patients with HCC and FAP may benefit from the development of new treatment options.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Initiate the pivotal Phase 3 trial of amezalpat in combination therapy for first-line HCC.
• Advance TPST-1495 into a Phase 2 study in patients with FAP in 2024 or early 2025.
• Disclose data from the TPST-1495 Phase 1 combination arm in patients with advanced endometrial cancer in 2025.

Key Dates

Keywords

Tempest Therapeutics, amezalpat, TPST-1120, TPST-1495, hepatocellular carcinoma, HCC, Familial Adenomatous Polyposis, FAP, Phase 3 trial, FDA, Roche, clinical trial, biotechnology, cancer therapy, NCI